Asia-Pacific medical foods for inborn errors of metabolism market are projected to register a CAGR of 15.3% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:
Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market By Products (Amino Acid, Low Protein Food, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Tyrosinemia Types I and II, Maple Syrup Urine Disease (MSUD), Homocystinuria, Glutaric Acidemia Type I, Urea Cycle Disorders, Methylmalonic Acidemia, Isovaleric Acidemia, Organic Acidurias, Renal Disease, Propionic Acidemia, Disorders of Leucine Metabolism, Others), Form (Powder, Liquids, Others), Packaging (Can, Packets, Bottle, Jar, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies, Others), Country (China, Japan, India, Australia, South Korea, Thailand, Singapore, Indonesia, Malaysia, New Zealand, Vietnam, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Asia-Pacific medical foods for inborn errors of metabolism market are:

- Increasing cases of diseases related to metabolic disorders

- Rising government initiatives towards providing or spreading awareness regarding medical foods for IEM
Market Players:

The key market players for Asia-Pacific medical foods for inborn errors of metabolism market are listed below:

- BioMarin
- Mead Johnson & Company, LLC. (A Subsidiary of Reckitt Benckiser Group plc.)
- Nestle Health Science (A Subsidiary of Nestle)
- Ajinomoto Cambrooke, Inc. (A Subsidiary of Ajinomoto Co., Inc.)
- Dr. Schar AG / SPA
- Nutricia (A Subsidiary of Danone)